Skip to main content
. 2020 Aug 3;43(10):2362–2370. doi: 10.2337/dc20-0300

Table 1.

Demographic and MMTT results for each C-peptide grouping

Cpepund Cpeplow Cpephigh P
N 11 9 10
n male/n female 5/6 6/3 5/5
Age (years) 40.09 ± 11.18 (26–58) 38.67 ± 14.73 (25–61) 35.80 ± 10.98 (18–52) 0.738
Age at diagnosis (years) 13.27 ± 4.50 (8–24) 16.56 ± 8.57 (8–32) 25.10 ± 8.20* (13–35) 0.003
Duration of diabetes (years) 26.82 ± 13.24 (13–47) 21.89 ± 13.34 (9–44) 10.70 ± 6.15* (3–20) 0.015
HbA1c (mmol/mol) 61.64 ± 10.64 (42–78) 58.11 ± 7.11 (51–74) 55.40 ± 8.47 (41–69) 0.297
HbA1c (%) 7.8 ± 3.1 (6.0–9.3) 7.5 ± 2.8 (6.8–8.9) 7.2 ± 2.9 (5.9–8.5)
BMI (kg/m2) 25.65 ± 3.27 24.20 ± 4.13 25.67 ± 4.04 0.259
Daily insulin (units) 39.93 ± 15.15 47.88 ± 23.21 38.30 ± 31.23 0.242
Insulin units/kg/day 0.54 ± 0.19 0.63 ± 0.25 0.49 ± 0.29 0.332
Method of control (n MDI/n CSII) 5/6 4/5 6/4
VO2peak (mL/kg/min) 35.61 ± 7.69 (21.05–49.00) 43.93 ± 9.03 (31.80–58.25) 35.67 ± 10.77 (21.25–51.00) 0.194
MMTT
 Peak C-peptide (pmol/L) 0.00 ± 0.00 (0–0) 42.00 ± 32.58* (4–83) 671.70 ± 435.15* (221–1,640) <0.001
 Median C-peptide 0.00 53.00 568.50
 AUC0–180 min C-peptide (pmol/L) 0.00 ± 0.00 6,026 ± 4,452* 89,459 ± 48,095* <0.001
 Peak glucagon (pmol/L) 14.04 ± 6.74 18.60 ± 13.49 12.45 ± 4.34 0.802
 AUC0–180 min glucagon (pmol/L) 1,557 ± 905.8 2,072 ± 1,370 1,259 ± 674.5 0.252
 Pre-MMTT glucose (mmol/L) 10.12 ± 3.38 9.55 ± 1.62 8.47 ± 3.15 0.428
 Peak glucose (mmol/L) 21.91 ± 2.75 20.03 ± 2.34 17.74 ± 3.59* 0.016
 ΔPre-MMTT to peak glucose (mmol/L) 11.76 ± 2.77 10.48 ± 2.12 9.27 ± 3.02* 0.045
Autoantibody positivity 6 of 11 7 of 9 8 of 10

Data are means ± SD unless otherwise indicated (data in parentheses are ranges). Boldface type indicates statistically significant P values. CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections.

*

Significantly different from Cpepund.

Significantly different from Cpeplow.